BACKGROUND: Cisplatinum (CP) is associated with acute kidney injury. The aim of this study was to define the spectrum of CP-induced nephrotoxicity in current practice. CASE-DIAGNOSIS/TREATMENT: A single-center, retrospective chart review was performed on children who received CP for treatment of a malignancy at the Hassenfeld Children's Center for Blood and Cancer Disorders of NYU Langone Medical Center between 2005 and 2012. Patients were considered to have nephrotoxicity if they had: (1) a decrease in estimated glomerular filtration rate (eGFR) of ≥30 % or (2) a decline in serum magnesium of ≥0.2 meq/L or (3) a decline in serum potassium of ≥0.2 meq/L. Thirty-two patients (mean age 8.0 ± 7.0 years) were included in this review, of whom 21 had a brain tumor (BT) and 11 had an osteosarcoma (OS); 31 (97 %) of the patients had a disturbance in renal function. The mean reduction in eGFR, serum magnesium and potassium was 37 ± 17, 30 ± 16 and 25 ± 14 %, respectively. The decline in eGFR, hypomagnesemia and hypokalemia was persistent in 38, 60 and 40 % of cases, respectively, through the short-term follow-up period. No patients required dialysis. CONCLUSIONS: Nearly all patients receiving CP in current care experience modest glomerular and tubular injury. The abnormalities persist in 40-60 % of cases during the short-term recovery period after CP treatment.
BACKGROUND:Cisplatinum (CP) is associated with acute kidney injury. The aim of this study was to define the spectrum of CP-induced nephrotoxicity in current practice. CASE-DIAGNOSIS/TREATMENT: A single-center, retrospective chart review was performed on children who received CP for treatment of a malignancy at the Hassenfeld Children's Center for Blood and Cancer Disorders of NYU Langone Medical Center between 2005 and 2012. Patients were considered to have nephrotoxicity if they had: (1) a decrease in estimated glomerular filtration rate (eGFR) of ≥30 % or (2) a decline in serum magnesium of ≥0.2 meq/L or (3) a decline in serum potassium of ≥0.2 meq/L. Thirty-two patients (mean age 8.0 ± 7.0 years) were included in this review, of whom 21 had a brain tumor (BT) and 11 had an osteosarcoma (OS); 31 (97 %) of the patients had a disturbance in renal function. The mean reduction in eGFR, serum magnesium and potassium was 37 ± 17, 30 ± 16 and 25 ± 14 %, respectively. The decline in eGFR, hypomagnesemia and hypokalemia was persistent in 38, 60 and 40 % of cases, respectively, through the short-term follow-up period. No patients required dialysis. CONCLUSIONS: Nearly all patients receiving CP in current care experience modest glomerular and tubular injury. The abnormalities persist in 40-60 % of cases during the short-term recovery period after CP treatment.
Authors: Jakob K Anninga; Hans Gelderblom; Marta Fiocco; Judith R Kroep; Antoni H M Taminiau; Pancras C W Hogendoorn; R Maarten Egeler Journal: Eur J Cancer Date: 2011-06-22 Impact factor: 9.162
Authors: Glenn M Chertow; Elisabeth Burdick; Melissa Honour; Joseph V Bonventre; David W Bates Journal: J Am Soc Nephrol Date: 2005-09-21 Impact factor: 10.121
Authors: Roderick Skinner; Annie Parry; Lisa Price; Michael Cole; Alan W Craft; Andrew D J Pearson Journal: Eur J Cancer Date: 2009-10-21 Impact factor: 9.162
Authors: Anne Blanchard; Rosa Vargas-Poussou; Marion Vallet; Aurore Caumont-Prim; Julien Allard; Estelle Desport; Laurence Dubourg; Matthieu Monge; Damien Bergerot; Stéphanie Baron; Marie Essig; Frank Bridoux; Ivan Tack; Michel Azizi Journal: J Am Soc Nephrol Date: 2014-07-10 Impact factor: 10.121
Authors: Erika Bíró; István Szegedi; Csongor Kiss; Anna V Oláh; Mark Dockrell; Robert G Price; Tamás Szabó Journal: BMC Pediatr Date: 2022-07-20 Impact factor: 2.567
Authors: Kelly R McMahon; Asaf Lebel; Shahrad Rod Rassekh; Kirk R Schultz; Tom D Blydt-Hansen; Geoffrey D E Cuvelier; Cherry Mammen; Maury Pinsk; Bruce C Carleton; Ross T Tsuyuki; Colin J D Ross; Louis Huynh; Mariya Yordanova; Frédérik Crépeau-Hubert; Stella Wang; Ana Palijan; Jasmine Lee; Debbie Boyko; Michael Zappitelli Journal: Pediatr Nephrol Date: 2022-10-19 Impact factor: 3.651
Authors: Alaa N A Fahmi; George S G Shehatou; Abdelhadi M Shebl; Hatem A Salem Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2016-05-23 Impact factor: 3.000
Authors: Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening Journal: Cochrane Database Syst Rev Date: 2019-03-11
Authors: Jaime N Wertman; Nicole Melong; Matthew R Stoyek; Olivia Piccolo; Stewart Langley; Benno Orr; Shelby L Steele; Babak Razaghi; Jason N Berman Journal: Elife Date: 2020-07-28 Impact factor: 8.140